Our Myolex® mission is to build the clinical standard to comprehensively assess and display changes in skeletal muscle composition and micro infrastructure to aid in the diagnosis, prognosis, and monitoring of neuromuscular disorders and muscle wasting diseases. We are deeply committed to helping the dedicated clinicians, scientists, caregivers, and above all, patients who are battling these diseases every day.
Our patented electrical impedance myography (EIM) technology was originally developed by Myolex co-founder Dr. Seward Rutkove, the Nancy Lurie Marks Chair of the Department of Neurology at Beth Israel Deaconess Medical Center, and Professor of Neurology at Harvard Medical School. To date, there are over 170 published clinical research papers about EIM, 10 issued patents, and over 10 pharmaceutical company-supported clinical studies.
Our Myolex mScan research device and data analytics platform is the first quantitative, comprehensive, sensitive, consistently reproducible, painless, and portable device that can be used to monitor and display the bioimpedance of muscle, at the individual or small group of muscle level, by measuring holistic changes in muscle composition and micro infrastructure.
Looking forward, our EIM technology holds great potential to 1) dramatically cut drug clinical trial costs while increasing patient retention, diversity, and in-home muscle measurement; 2) aid in the early disease diagnosis for neuromuscular disorders such as ALS, and 3) even replace far more expensive, non-portable, and often traumatic muscle measurement devices, such as magnetic resonance imaging (MRI), for specific muscle groups and when their clinical imaging advantages are unnecessary.